GLP-1 vs Glucagon: In-Depth Analysis of Peptide Category Comparison
Abstract: This in-depth analysis compares glucagon-like peptide-1 (GLP-1) and glucagon, two critical peptide hormones with divergent metabolic roles. GLP-1 agonists dominate the diabetes and obesity market (projected $100B+ by 2030), while glucagon is primarily used for severe hypoglycemia. We evaluate product parameters (half-life, receptor affinity), technical advantages (GLP-1: sustained weight loss; glucagon: rapid glucose mobilization), and brand comparisons (Novo Nordisk’s Ozempic vs. Eli Lilly’s Mounjaro). The analysis covers industry trends, factory certifications (GMP, FDA), logistics (cold-chain stability), and selection criteria for peptides, emphasizing purity (>98%) and third-party testing. Current market data indicates GLP-1’s 15% CAGR versus glucagon’s niche growth, highlighting distinct application scopes and regulatory landscapes.